Pediatric central nervous system (CNS) tumors are the second most common childhood malignancy and the most common solid tumor in children. Approximately 4,000 children and adolescents in the US are diagnosed with primary brain tumors each year. Primary brain tumors start in the brain and generally do not spread outside the brain tissue.
Symptoms vary depending on the size and location of the tumour and can occur a bit differently in each child. Growing tumors may cause increased pressure on the brain in the limited space in the skull. This is called increased intracranial pressure or ICP. This is not usually the case in babies, since their skull bones have not fully grown together. The most common symptoms include
In addition to a complete medical history and physical examination of the child, examination procedures for a brain tumor may include a neurological exam, CT, PET or MRI scan, X-ray, angiogram, myelogram, and lumbar puncture. Combinations of surgery, radiation therapy, and chemotherapy are mainly used for the treatment of pediatric brain tumors.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market
The Pediatric Brain Tumors market report also covers emerging drugs, current treatment practices, Pediatric Brain Tumors market share of the individual therapies, current and forecasted Pediatric Brain Tumors Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Pediatric Brain Tumors treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Pediatric Brain Tumors Market Key Facts
-
According to the study published by Johnson et al., there are >100 different histological subtypes of CNS tumors with the incidence of each varying by age and histologic subtype. Childhood CNS tumour incidence varies by country from 1.12–5.14 cases per 100,000 persons with the highest incidence in the United States.
-
According to the American Cancer Society, brain and spinal cord tumors are the second most common cancers in children (after leukaemia). They account for about 1 out of 4 childhood cancers. More than 4,000 brain and spinal cord tumors are diagnosed each year in children and teens. The incidence rate (number of tumors per 100,000 children) has not changed much in recent years.
-
In children, the incidence of brain cancer is approximately 4.84 per 100,000, according to the National Cancer Institute.
-
As per Cancer.Net, about 3,540 children under the age of 15 were likely to be diagnosed with a brain or CNS tumour in 2020.
-
Key Benefits of Pediatric Brain Tumors Market Report
-
Pediatric Brain Tumors market report provides an in-depth analysis of Pediatric Brain Tumors Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Pediatric Brain Tumors market report will help in developing business strategies by understanding the Pediatric Brain Tumors Market trends & developments, key players, and future market competition that will shape and drive the Pediatric Brain Tumors market in the upcoming years.
-
The Pediatric Brain Tumors market report covers Pediatric Brain Tumors current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Pediatric Brain Tumors market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Pediatric Brain Tumors market size is expected to increase during the forecast period owing to the rise in the number of incident cases in the 7MM.
The Pediatric Brain Tumors market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Pediatric Brain Tumors market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Pediatric Brain Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Pediatric Brain Tumors Epidemiology
The Pediatric Brain Tumors epidemiology section covers insights about the historical and current Pediatric Brain Tumors patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Pediatric Brain Tumors Epidemiology Segmentation
-
Total Incident cases of Pediatric brain tumors
-
Gender-specific Incident cases of Pediatric brain tumors
-
Diagnosed and Treatable cases of Pediatric brain tumors
-
Type-specific Incident cases of Pediatric brain tumors
Pediatric Brain Tumors Drugs Uptake and Key Market Players
The Pediatric Brain Tumors Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Brain Tumors market or expected to get launched in the market during the study period. The analysis covers Pediatric Brain Tumors market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Pediatric brain tumors market is anticipated to change in the coming years owing to the improvement in the rise in healthcare spending across the world.
Currently, there are several potential players with their promising therapies in the early and mid-stages of clinical development. There is an unmet clinical need for a therapeutic treatment that addresses the root cause of Pediatric brain tumors.
Pediatric Brain Tumors Companies:
Oncoceutics
Novartis
Ziopharm
Laminar Pharmaceuticals
Cellectar Biosciences
Moleculin Biotech
And many others.
Pediatric Brain Tumors Therapies covered in the report include:
Everolimus
LP561A1
Ad-RTS-hIL-12 + veledimex
ONC201
CLR-131
WP1066
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Pediatric Brain Tumors Competitive Intelligence Analysis
4. Pediatric Brain Tumors Market Overview at a Glance
5. Pediatric Brain Tumors Disease Background and Overview
6. Pediatric Brain Tumors Patient Journey
7. Pediatric Brain Tumors Epidemiology and Patient Population
8. Pediatric Brain Tumors Treatment Algorithm, Current Treatment, and Medical Practices
9. Pediatric Brain Tumors Unmet Needs
10. Key Endpoints of Pediatric Brain Tumors Treatment
11. Pediatric Brain Tumors Marketed Products
12. Pediatric Brain Tumors Emerging Therapies
13. Pediatric Brain Tumors Seven Major Market Analysis
14. Attribute Analysis
15. Pediatric Brain Tumors Market Outlook (7 major markets)
16. Pediatric Brain Tumors Access and Reimbursement Overview
17. KOL Views on the Pediatric Brain Tumors Market.
18. Pediatric Brain Tumors Market Drivers
19. Pediatric Brain Tumors Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/pediatric-brain-tumors-market
Latest Reports By DelveInsight
Lennox Gastaut Syndrome Market
DelveInsight’ s “Lennox Gastaut Syndrome Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Lennox Gastaut Syndrome market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Chronic Hand Eczema (CHE) Market
DelveInsight’ s “Chronic Hand Eczema (CHE) Market Insights, Epidemiology, and Market Forecast 2030” report provide a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Chronic Hand Eczema (CHE) market size, share, trends, growth and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/